Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 + Bevacizumab in Advanced Colorectal Cancer
NCT07722494Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jul 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 3 trial of IBI363 in colorectal cancer (CRC), sponsored by Innovent Biologics. Started Jul 2026; status: recruiting.
02
Drugs
IBI363
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07722494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722494.